MCID: ALL006
MIFTS: 59

Allergic Asthma

Categories: Respiratory diseases, Immune diseases

Aliases & Classifications for Allergic Asthma

MalaCards integrated aliases for Allergic Asthma:

Name: Allergic Asthma 12 25 15 73
Extrinsic Asthma with Acute Exacerbation 12
Extrinsic Asthma with Status Asthmaticus 12
Atopic Asthma, Susceptibility to 6
Ige-Mediated Allergic Asthma 73
Extrinsic Asthma 25
Asthma Allergic 55
Atopic Asthma 12

Classifications:



Summaries for Allergic Asthma

Genetics Home Reference : 25 Asthma is a breathing disorder characterized by inflammation of the airways and recurrent episodes of breathing difficulty. These episodes, sometimes referred to as asthma attacks, are triggered by irritation of the inflamed airways. In allergic asthma, the attacks occur when substances known as allergens are inhaled, causing an allergic reaction. Allergens are harmless substances that the body's immune system mistakenly reacts to as though they are harmful. Common allergens include pollen, dust, animal dander, and mold. The immune response leads to the symptoms of asthma. Allergic asthma is the most common form of the disorder.

MalaCards based summary : Allergic Asthma, also known as extrinsic asthma with acute exacerbation, is related to aspergillosis and helicobacter pylori infection, and has symptoms including coughing, wheezing and shortness of breath or has_symptom rapid breathing. An important gene associated with Allergic Asthma is MS4A2 (Membrane Spanning 4-Domains A2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Montelukast have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. Allergic asthma is airway obstruction and inflammation that is partially reversible with medication. The disease has symptom coughing, has symptom wheezing, has symptom shortness of breath or has symptom rapid breathing, and has symptom chest tightness.

Related Diseases for Allergic Asthma

Diseases related to Allergic Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 31.9 CCL17 IFNG IL10 IL4 IL5
2 helicobacter pylori infection 30.9 CCL5 IFNG IL10
3 intrinsic asthma 30.8 IL4 IL5 RNASE3
4 respiratory syncytial virus infectious disease 30.8 CCL5 IL13 IL5
5 eosinophilic gastroenteritis 30.8 CCL11 IL5 RNASE3
6 ige responsiveness, atopic 30.4 IFNG IGHE IL10 IL13 IL4 IL4R
7 esophagitis 30.4 CCL11 IL13 IL5 TSLP
8 rhinitis 30.3 CCL11 CCL5 IGHE IL13 IL4 IL4R
9 pneumonia 30.3 CCL11 CCL5 IL10 IL13 IL5
10 periodontitis 30.2 IFNG IL10 IL17A IL4
11 toxocariasis 30.1 IGHE RNASE3
12 vernal keratoconjunctivitis 29.8 CCL11 CCL5 IL13 IL4 IL5 RNASE3
13 esophagitis, eosinophilic, 1 29.8 CCL11 IL13 IL5 STAT6 TSLP
14 gastroenteritis 29.8 CCL11 IFNG IL10 IL4 IL5 RNASE3
15 pulmonary eosinophilia 29.7 CCL11 CCL17 CCL5 IL13 IL4 IL5
16 rheumatoid arthritis 29.6 CCL5 IFNG IL10 IL17A IL4
17 contact dermatitis 29.5 CCL17 IFNG IL10 IL17A IL4 IL5
18 keratoconjunctivitis 29.4 CCL11 CCL17 IFNG IL13 IL4 IL5
19 allergic rhinitis 29.1 CCL11 IFNG IGHE IL10 IL13 IL4
20 food allergy 28.8 IFNG IL10 IL13 IL4 IL5 MS4A2
21 pulmonary disease, chronic obstructive 28.5 ADAM33 CCL11 CCL5 IL13 IL17A RNASE3
22 dermatitis 27.8 CCL11 CCL17 IFNG IGHE IL13 IL17A
23 dermatitis, atopic 25.0 CCL11 CCL17 CCL5 GATA3 IFNG IGHE
24 asthma 24.2 ADAM33 CCL11 CCL17 CCL5 GATA3 IFNG
25 mycoplasmal pneumonia 11.0 IFNG IL4
26 cytokine deficiency 11.0 IL13 IL5
27 tropical endomyocardial fibrosis 10.9 IL10 IL4
28 eosinophilic fasciitis 10.9 IFNG IL5
29 loeffler endocarditis 10.9 IL5 RNASE3
30 angioimmunoblastic lymphadenopathy with dysproteinemia 10.9 IL13 IL5
31 egg allergy 10.9 IGHE IL4 IL5
32 staphylococcal toxic shock syndrome 10.9 IFNG IGHE
33 pemphigoid gestationis 10.9 CCL11 IL5
34 cough variant asthma 10.9 IL4 IL5 RNASE3
35 chronic tic disorder 10.9 IL13 IL4 IL5
36 blepharoconjunctivitis 10.9 CCL11 IL4 RNASE3
37 giant papillary conjunctivitis 10.8 CCL11 IL4 RNASE3
38 ascaridiasis 10.8 IL10 IL13
39 hyperlucent lung 10.8 IFNG IL10 IL4
40 african tick-bite fever 10.8 CCL5 IFNG IL13
41 baylisascariasis 10.8 IFNG IL10 IL4
42 night blindness, congenital stationary, type 1a 10.8 CCL11 IL13 IL5
43 cow milk allergy 10.8 IL10 IL5 RNASE3
44 ascaris lumbricoides infection 10.8 IL13 IL5 TSLP
45 sinusitis 10.8 IL4R IL5 RNASE3
46 buruli ulcer 10.8 IFNG IL10 IL4
47 tungiasis 10.8 IL10 IL4
48 poliomyelitis 10.8 IFNG IL10 IL4
49 status asthmaticus 10.8 CCL5 IL5 RNASE3
50 multicentric castleman disease 10.8 IFNG IL10 IL5

Graphical network of the top 20 diseases related to Allergic Asthma:



Diseases related to Allergic Asthma

Symptoms & Phenotypes for Allergic Asthma

Symptoms:

12
  • coughing
  • wheezing
  • shortness of breath or has_symptom rapid breathing
  • chest tightness

MGI Mouse Phenotypes related to Allergic Asthma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 IL13 CCL11 CCL17 CCL5 IL16 GATA3
2 immune system MP:0005387 10.19 CCL11 CCL17 CCL5 IL16 GATA3 IL17A
3 digestive/alimentary MP:0005381 10.06 IL13 GATA3 IL17A IFNG IL4 IL10
4 endocrine/exocrine gland MP:0005379 10.02 IL13 GATA3 IL17A IFNG IL4 IL10
5 integument MP:0010771 9.76 IL13 GATA3 IFNG IL4 IL4R IL10
6 no phenotypic analysis MP:0003012 9.5 IL13 GATA3 IL17A IFNG IL4 IL10
7 respiratory system MP:0005388 9.36 IL13 CCL11 IL17A IFNG IL4 IL10

Drugs & Therapeutics for Allergic Asthma

Drugs for Allergic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 242138-07-4
2
Montelukast Approved Phase 4,Phase 3,Phase 2,Not Applicable 158966-92-8 5281040
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 75614-87-8, 51-45-6 774
4
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90566-53-3 62924
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
6
Budesonide Approved Phase 4,Phase 2,Phase 3 51333-22-3 63006 5281004
7
Norepinephrine Approved Phase 4 51-41-2 439260
8
Theophylline Approved Phase 4 58-55-9 2153
9
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 10102-43-9 145068 160954
10
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
11
Terbutaline Approved Phase 4 23031-25-6 5403
12
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
13
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
14
Metronidazole Approved Phase 4 443-48-1 4173
15
Vancomycin Approved Phase 4 1404-90-6 441141 14969
16
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
17
Histamine Phosphate Phase 4,Phase 3,Phase 2,Not Applicable 51-74-1 65513
18 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Adrenergic beta-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Formoterol Fumarate Phase 4,Phase 2,Phase 3
24 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Allergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
34 Leukotriene Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 mometasone furoate Phase 4,Phase 3,Phase 2
39
Salmeterol xinafoate Phase 4,Not Applicable 94749-08-3 56801
40 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
42 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Not Applicable
43 Adrenergic alpha-Agonists Phase 4
44 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
45 Albuterol Phase 4,Phase 2,Phase 3,Phase 1
46 Tocolytic Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Vasoconstrictor Agents Phase 4
49 Viscosupplements Phase 4
50 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 236)
# Name Status NCT ID Phase Drugs
1 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
2 mRNA Expression as a Biomarker of Omalizumab Response Unknown status NCT01584687 Phase 4
3 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
4 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed NCT00870584 Phase 4 Omalizumab;Placebo
5 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4 omalizumab at a dose of 0.016mg/kg/IU/mL;Placebo
6 Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00691873 Phase 4 Placebo;Xolair
7 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy Completed NCT00639691 Phase 4
8 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed NCT00264849 Phase 4 Omalizumab
9 Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy Completed NCT00329381 Phase 4 Xolair;Xolair
10 Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4 Omalizumab;Inhaled corticosteroids (ICS);Long-acting beta 2-adrenergic agonist (LABA);Short-acting beta 2-adrenergic agonist (SABA)
11 Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Completed NCT00490425 Phase 4 Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
12 Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen Completed NCT00518518 Phase 4 Staloral 300;placebo
13 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
14 Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4 Placebo;Xolair
15 Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils Completed NCT02023151 Phase 4 Omalizumab
16 A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy Completed NCT01125748 Phase 4 Omalizumab;Placebo;Asthma therapies
17 Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma Completed NCT00980707 Phase 4 Inhaled corticosteroid (fluticasone)
18 Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Completed NCT00492076 Phase 4
19 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy Completed NCT00283504 Phase 4 ANTI-IGE THERAPY (XOLAIR)
20 Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma Completed NCT00546143 Phase 4 Omalizumab;Omalizumab;Omalizumab
21 A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) Completed NCT01922037 Phase 4 Omalizumab
22 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma Completed NCT00454051 Phase 4 Omalizumab;placebo
23 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4 omalizumab (Xolair);placebo
24 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
25 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
26 Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4 budesonide and montelukast;budesonide and formoterol;montelukast;budesonide;placebo
27 The Effect of Xolair (Omalizumab) on Allergy Blood Cells Completed NCT00657891 Phase 4 Omalizumab;Placebo
28 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations Completed NCT01430403 Phase 4 Inhaled Corticosteroid Boost Therapy (ICS)
29 C1-inhibitor in Allergic ASThma Patients Recruiting NCT03051698 Phase 4 C1-inhibitor;Antibiotics
30 Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280) Terminated NCT00070707 Phase 4 Nasonex
31 No Resistance After Long Term Treatment SERETIDE Withdrawn NCT00456313 Phase 4 FLIXOTIDE and SERETIDE
32 A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma Withdrawn NCT00242359 Phase 4 omalizumab
33 Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations Unknown status NCT01520051 Phase 3 Mepolizumab;Placebo
34 Omalizumab in Non-atopic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
35 Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma Completed NCT01976208 Phase 2, Phase 3 Omalizumab;placebo
36 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy Completed NCT01202903 Phase 3 Omalizumab;Placebo
37 Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis Completed NCT00396409 Phase 3 Depigoid;Omalizumab;Placebo
38 Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Completed NCT00829179 Phase 3 RhuMab-E25
39 Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children Completed NCT01328886 Phase 3 Omalizumab
40 Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma Completed NCT00482248 Phase 3 Omalizumab
41 A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma Completed NCT00109200 Phase 3 Xolair (omalizumab)
42 Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma Completed NCT00986323 Phase 3
43 Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) Completed NCT01155700 Phase 3 omalizumab
44 Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma Completed NCT00079937 Phase 3 Omalizumab;Placebo;Fluticasone
45 Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. Completed NCT00500539 Phase 3 omalizumab
46 Fish Oil and Asthma in House Dust Mite Allergy Completed NCT00380926 Phase 2, Phase 3 polyunsatturated fatty acids (fish oil)
47 A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Completed NCT02596321 Phase 3 Mitizax;Placebo
48 Efficacy Of Bacterial Lysate In Asthmatic Children Completed NCT02541331 Phase 3
49 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED) Completed NCT00289874 Phase 3 montelukast sodium;Comparator: Placebo
50 Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients Completed NCT00482508 Phase 3 Omalizumab

Search NIH Clinical Center for Allergic Asthma

Genetic Tests for Allergic Asthma

Anatomical Context for Allergic Asthma

MalaCards organs/tissues related to Allergic Asthma:

41
Lung, T Cells, Testes, Skin, Neutrophil, B Cells, Smooth Muscle

Publications for Allergic Asthma

Articles related to Allergic Asthma:

(show top 50) (show all 856)
# Title Authors Year
1
Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma. ( 29881388 )
2018
2
The effects of bone marrow-derived mesenchymal stem cells on ovalbumin-induced allergic asthma and cytokine responses in mice. ( 29922428 )
2018
3
Advances and Evolving Concepts in Allergic Asthma. ( 29427987 )
2018
4
Expansion of a CD26<sup>low</sup>effector TH subset and reduction of circulating levels of sCD26 in stable allergic asthma in adults. ( 29297467 )
2018
5
Dexamethasone alleviates allergic asthma immature rat through Toll like receptor 4. ( 29364486 )
2018
6
Modeling Unobserved Heterogeneity in Susceptibility to Ambient Benzo[a]pyrene Concentration among Children with Allergic Asthma Using an Unsupervised Learning Algorithm. ( 29320438 )
2018
7
Does adiposity mediate the relationship between socioeconomic position and non-allergic asthma in childhood? ( 29367283 )
2018
8
Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? ( 29879991 )
2018
9
Subcutaneous immunotherapy suppresses Th2 inflammation and induces neutralizing antibodies, but sublingual immunotherapy suppresses airway hyperresponsiveness in grass pollen mouse models for allergic asthma. ( 29752757 )
2018
10
Subcutaneous allergen immunotherapy may be a suitable treatment for exacerbator allergic asthma. ( 29803710 )
2018
11
Developmental endothelial locus-1 (Del-1) antagonizes Interleukin-17-mediated allergic asthma. ( 29437247 )
2018
12
March1 E3 Ubiquitin Ligase Modulates Features of Allergic Asthma in an Ovalbumin-Induced Mouse Model of Lung Inflammation. ( 29854835 )
2018
13
Is eosinophilic esophagitis an equivalent of pollen allergic asthma? Analysis of biopsies and therapy guided by component resolved diagnosis. ( 29338961 )
2018
14
Intranasal administration of probiotic Lactobacillus rhamnosus GG prevents birch pollen-induced allergic asthma in a murine model. ( 29888398 )
2018
15
Allergic asthma is associated with increased risk of infections requiring antibiotics. ( 29413341 )
2018
16
Role of neutrophils in allergic asthma. ( 29883877 )
2018
17
Long Sun-Exposures Influencing High Sub-Cutaneous Synthesis of Vitamin-D3 may be Associated with Exacerbation of Symptoms in Allergic-Asthma. ( 29755960 )
2018
18
Initial Influenza Virus Replication Can Be Limited in Allergic Asthma Through Rapid Induction of Type III Interferons in Respiratory Epithelium. ( 29867963 )
2018
19
Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. ( 29318574 )
2018
20
Author Correction: A gammaherpesvirus provides protection against allergic asthma by inducing the replacement of resident alveolar macrophages with regulatory monocytes. ( 29955109 )
2018
21
Immune Homeostasis: Effects of Chinese Herbal Formulae and Herb-Derived Compounds on Allergic Asthma in Different Experimental Models. ( 29752613 )
2018
22
Activated Leukocyte Cell Adhesion Molecule Stimulates the T Cell Response in Allergic Asthma. ( 29394080 )
2018
23
Dephosphorylated Polymerase I and Transcript Release Factor Prevents Allergic Asthma Exacerbations by Limiting IL-33 Release. ( 29977243 )
2018
24
5-BDBD ameliorates an OVA-induced allergic asthma by the reduction of Th2 cytokines production. ( 29796218 )
2018
25
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. ( 29422778 )
2018
26
IL-37 inhibits IL-4/IL-13-induced CCL11 production and lung eosinophilia in murine allergic asthma. ( 29319845 )
2018
27
Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab? ( 29741411 )
2018
28
Increased Susceptibility to Allergic Asthma with the Impairment of Respiratory Tolerance Caused by Psychological Stress. ( 29874662 )
2018
29
Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab. ( 29300536 )
2018
30
Biased Generation and In Situ Activation of Lung Tissue-Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma. ( 29343554 )
2018
31
Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. ( 29977648 )
2018
32
Can natural killer cells represent an early life immune response in development of allergic asthma? More precise data analysis should be considered. ( 29945813 )
2018
33
Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. ( 29302700 )
2018
34
Hypergravity enhances the therapeutic effect of dexamethasone in allergic asthma and rhinitis animal model. ( 29772010 )
2018
35
Cost effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. ( 28532191 )
2017
36
Corrigendum: Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. ( 28936430 )
2017
37
Omalizumab in non-allergic Asthma: A report of 13 cases. ( 28800272 )
2017
38
Inhibitory effects of l-theanine on airway inflammation in ovalbumin-induced allergic asthma. ( 27908701 )
2017
39
Bupleurum chinense extract ameliorates an OVA-induced murine allergic asthma through the reduction of the Th2 and Th17 cytokines production by inactivation of NFI_B pathway. ( 28531919 )
2017
40
The C5a/C5aR1 axis controls the development of experimental allergic asthma independent of LysM-expressing pulmonary immune cells. ( 28931049 )
2017
41
Deficiency of KLF4 compromises the lung function in an acute mouse model of allergic asthma. ( 28867182 )
2017
42
The Differences in Serum Quantitative Specific IgE Levels Induced by Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis Sensitization in Intermittent and Persistent Allergic Asthma. ( 29348379 )
2017
43
Trigonella foenum-graecum alleviates airway inflammation of allergic asthma in ovalbumin-induced mouse model. ( 27939889 )
2017
44
Murine Models of Allergic Asthma. ( 28063042 )
2017
45
Involvements of p38 MAPK and oxidative stress in the ozone-induced enhancement of AHR and pulmonary inflammation in an allergic asthma model. ( 29284473 )
2017
46
The Effect of Zataria multiflora on Th1/Th2 and Th17/T Regulatory in a Mouse Model of Allergic Asthma. ( 28824424 )
2017
47
Chlamydia pneumoniae Induces Interferon Gamma Responses in Peripheral Blood Mononuclear Cells in Children with Allergic Asthma. ( 28480606 )
2017
48
Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models. ( 28835901 )
2017
49
Effect of personal exposure to black carbon on changes in allergic asthma gene methylation measured 5A days later in urban children: importance of allergic sensitization. ( 28588744 )
2017
50
Response to omalizumab in patients with severe allergic asthma: A real-life study. ( 28947015 )
2017

Variations for Allergic Asthma

ClinVar genetic disease variations for Allergic Asthma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MS4A2 NM_000139.4(MS4A2): c.710A> G (p.Glu237Gly) single nucleotide variant risk factor rs569108 GRCh37 Chromosome 11, 59863104: 59863104
2 MS4A2 NM_000139.4(MS4A2): c.710A> G (p.Glu237Gly) single nucleotide variant risk factor rs569108 GRCh38 Chromosome 11, 60095631: 60095631

Expression for Allergic Asthma

Search GEO for disease gene expression data for Allergic Asthma.

Pathways for Allergic Asthma

Pathways related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CCL11 CCL5 GATA3 IFNG IGHE IL10
2
Show member pathways
13.85 CCL11 CCL17 CCL5 IL10 IL13 IL16
3
Show member pathways
13.72 CCL11 CCL17 CCL5 IFNG IL10 IL13
4
Show member pathways
13.56 CCL11 CCL17 CCL5 IFNG IL10 IL13
5
Show member pathways
13.45 CCL11 CCL17 CCL5 IL10 IL13 IL16
6
Show member pathways
13.4 CCL11 CCL5 GATA3 IFNG IGHE IL10
7
Show member pathways
13.35 CCL11 CCL17 CCL5 IL10 IL13 IL16
8
Show member pathways
12.94 CCL11 IFNG IL10 IL13 IL17A IL4
9
Show member pathways
12.9 CCL11 GATA3 IGHE IL4 IL4R STAT6
10 12.84 IFNG IL13 IL4 IL4R IL5 STAT6
11
Show member pathways
12.7 IFNG IL10 IL13 IL16 IL17A IL4
12 12.65 CCL5 GATA3 IFNG IL10 IL17A IL4
13
Show member pathways
12.63 IGHE IL13 IL4 IL5 ITK MS4A2
14
Show member pathways
12.53 GATA3 IFNG IL10 IL17A IL4 IL5
15
Show member pathways
12.51 GATA3 IFNG IL10 IL13 IL17A IL4
16
Show member pathways
12.43 CCL11 CCL17 IFNG IL13 IL17A IL4
17
Show member pathways
12.23 GATA3 IFNG IL10 IL17A
18
Show member pathways
12.12 CCL11 CCL17 CCL5 IFNG IL10 IL13
19 12 IFNG IL10 IL4 IL5
20 11.91 GATA3 IFNG IL13 IL4 IL5
21 11.9 IFNG IL10 IL4R STAT6
22 11.83 IL4 IL4R IL5
23 11.83 GATA3 IFNG IL10 IL13 IL17A IL4
24
Show member pathways
11.81 GATA3 IFNG IL4 IL5
25 11.8 CCL5 IFNG IL17A
26 11.78 CCL11 CCL5 IL13 IL4 IL5
27 11.72 GATA3 IL10 IL5
28 11.67 CCL11 GATA3 IGHE IL10 IL13 IL17A
29 11.61 CCL5 IL10 IL13 IL4
30 11.56 CCL11 CCL17 IGHE IL10 IL4 IL4R
31 11.5 CCL11 STAT6 TSLP
32 11.43 IFNG IL4 IL4R IL5
33 11.39 IFNG IL10 IL13 IL4 IL5
34 11.31 IFNG IL10 IL13 IL4 IL5
35 11.31 GATA3 IFNG IL13 IL17A IL4 IL5
36 10.98 CCL11 CCL17 GATA3 IFNG IL10 IL13

GO Terms for Allergic Asthma

Cellular components related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CCL11 CCL17 CCL5 IFNG IGHE IL10
2 external side of plasma membrane GO:0009897 9.46 IGHE IL13 IL17A MS4A2
3 extracellular space GO:0005615 9.44 CCL11 CCL17 CCL5 IFNG IL10 IL13

Biological processes related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.9 CCL11 CCL17 CCL5 IFNG IL10 IL13
2 chemotaxis GO:0006935 9.89 CCL11 CCL17 CCL5 IL16
3 inflammatory response GO:0006954 9.86 CCL11 CCL17 CCL5 IL10 IL13 IL17A
4 cellular response to tumor necrosis factor GO:0071356 9.84 CCL11 CCL17 CCL5 GATA3
5 cellular response to interferon-gamma GO:0071346 9.82 CCL11 CCL17 CCL5
6 chemokine-mediated signaling pathway GO:0070098 9.81 CCL11 CCL17 CCL5
7 neutrophil chemotaxis GO:0030593 9.8 CCL11 CCL17 CCL5
8 response to virus GO:0009615 9.78 CCL11 CCL5 GATA3 IFNG
9 immune response GO:0006955 9.77 CCL11 CCL17 CCL5 IFNG IGHE IL10
10 cellular response to interleukin-1 GO:0071347 9.76 CCL11 CCL17 CCL5 IL17A
11 monocyte chemotaxis GO:0002548 9.75 CCL11 CCL17 CCL5
12 positive regulation of B cell proliferation GO:0030890 9.74 IL13 IL4 IL5
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CCL5 IFNG IL13 TSLP
14 lymphocyte chemotaxis GO:0048247 9.7 CCL11 CCL17 CCL5
15 leukocyte chemotaxis GO:0030595 9.65 IL10 IL16
16 positive regulation of mast cell degranulation GO:0043306 9.63 IL13 IL4R
17 positive regulation of interleukin-5 production GO:0032754 9.62 GATA3 TSLP
18 positive regulation of immunoglobulin production GO:0002639 9.62 IL13 IL4R
19 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 GATA3 IL10 IL13 IL4
20 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 IL4
21 positive regulation of interleukin-5 secretion GO:2000664 9.61 GATA3 TSLP
22 positive regulation of macrophage activation GO:0043032 9.61 IL10 IL13 IL4R
23 type 2 immune response GO:0042092 9.6 IL10 IL4
24 positive regulation of interleukin-23 production GO:0032747 9.58 IFNG IL17A
25 regulation of isotype switching GO:0045191 9.56 IL10 IL4
26 interleukin-4-mediated signaling pathway GO:0035771 9.55 IL4R STAT6
27 positive regulation of interleukin-13 production GO:0032736 9.54 GATA3 IL4 TSLP
28 positive regulation of isotype switching to IgE isotypes GO:0048295 9.51 IL4 STAT6
29 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
30 cytokine-mediated signaling pathway GO:0019221 9.4 CCL11 CCL5 GATA3 IGHE IL10 IL13

Molecular functions related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL11 CCL17 CCL5
2 cytokine activity GO:0005125 9.36 CCL11 CCL17 CCL5 IFNG IL10 IL13
3 CCR chemokine receptor binding GO:0048020 9.33 CCL11 CCL17 CCL5
4 CCR4 chemokine receptor binding GO:0031729 8.96 CCL17 CCL5

Sources for Allergic Asthma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....